Orthocell (ASX:OCC) was granted a medical device license by Health Canada to start sales of its nerve repair collagen wrap Remplir in the country, according to a Wednesday Australian bourse filing.
The firm noted that the approval was granted earlier than expected after it lodged an application in February.
The company is currently in talks to appoint non-exclusive local specialist distribution partners in Canada to drive market penetration, and the first sales are expected in the second half, the filing said.
Orthocell's shares surged past 13% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.